Trial reportQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2009
Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial.
Trial report in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03341286 (Randomized, Placebo Controlled, Phase II Trial, on the Effect of an Oral Supplement,TK3), which is not on this map. Cited by 17 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized, Placebo Controlled, Phase II Trial, on the Effect of an Oral Supplement,TK3 (Tryptophan and Thiamine) on the Quality of Life and Chemotherapy Tolerance in Cancer Patients With Advanced Disease.
Who cites it
17 citing papers in PubMed, 6 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Utility Values of Health Status in Gastric Cancer: A Systematic Review.Value in health regional issues · 2025Pooled it
- Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma.The oncologist · 2021Pooled it
- Reporting of health-related quality of life in randomized controlled trials involving palliative systemic therapy for esophagogastric cancer: a systematic review.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2018Pooled it
- Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer.The Cochrane database of systematic reviews · 2017Pooled it
- Chemotherapy for advanced gastric cancer.The Cochrane database of systematic reviews · 2017Pooled it
- Effective palliation and quality of life outcomes in studies of surgery for advanced, non-curative gastric cancer: a systematic review.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2012Pooled it
- Quality of life in the trastuzumab for gastric cancer trial.The oncologist · 2014Trial
- Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study.Journal of cancer research and clinical oncology · 2014Trial
- Real-world survival benefit of chemotherapy in elderly patients with advanced gastric cancer: a population-based SEER analysis.Scientific reports · 2026Article
- Health-Related Quality of Life in Patients With Locally Advanced Gastric Cancer Undergoing Perioperative or Postoperative Adjuvant S-1 Plus Oxaliplatin With D2 Gastrectomy: A Propensity Score-Matched Cohort Study.Frontiers in oncology · 2022Article
- Cost-utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2021Article
- Review
- Estimation of population-based utility weights for gastric cancer-related health states.Patient preference and adherence · 2018Article
- Targeted literature review of the global burden of gastric cancer.Ecancermedicalscience · 2018Review
- Construction of quality of life change patterns: example in oncology in a phase III therapeutic trial (FFCD 0307).Health and quality of life outcomes · 2015Article
- In reply.Deutsches Arzteblatt international · 2015Article
- Measuring patient-reported outcomes in advanced gastric cancer.Ecancermedicalscience · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 10 institutions in 9 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe quality of life (QL) of advanced gastric cancer patients receiving irinotecan, folinic acid and 5-fluorouracil (5-FU) (IF arm) or cisplatin with 5-FU (CF arm) is presented.
methodsPatients with measurable or evaluable advanced gastric cancer received IF weekly for 6/7 weeks or CF q4 weeks. QL was assessed using the EORTC QLQ-C30 at baseline, subsequently every 8 weeks until progression and thereafter every 3 months until death. The QL data were analysed using several statistical methods including summary measures and pattern-mixture modelling.
resultsA total of 333 patients were randomised and treated (IF 170, CF 163). The time-to-progression for IF and CF was 5.0 and 4.2 months (P = 0.088), respectively. The overall compliance rates for QL questionnaire completion were 60 and 56% in the IF and CF arms, respectively. Significant treatment differences were observed for the physical functioning scale (P = 0.024), nausea\vomiting (P = 0.001) and EQ-5D thermometer (P = 0.020) in favour of the IF treatment arm.
conclusionThere was a trend in favour of IF over CF in time-to-progression. The IF group also demonstrated a better safety profile than CF and a better QL on a number of multi-item scales, suggesting that IF offers an alternative first-line platinum-free treatment option for advanced gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.